Healx, a Cambridge, UK-based AI-enabled, clinical-stage biotech firm specializing in uncommon illnesses, raised $47m in Sequence C funding.
The spherical was co-led by R42 Group and Atomico, with participation from new and current buyers together with Balderton, Jonathan Milner, World Mind, btov, Ayana Capital, o2h and VU Enterprise Companions. Together with the financing, Stanford Medication Adjunct Professor Ronjon Nag, Ph.D., founding father of R42 Group and 2024 Silicon Valley Corridor of Fame AI inductee, joined the board of Healx.
The corporate, which has raised roughly $110m to this point, intends to make use of the proceeds to advance its pipeline of medicines in uncommon oncology, renal and neurodevelopmental problems, together with advancing its lead program HLX-1502 by means of a Section 2 scientific trial for the remedy of neurofibromatosis Kind 1 (NF1).
Co-founded in Cambridge (UK) by its chairman and Viagra co-inventor David Brown, Ph.D., and Tim Guilliams, Ph.D., CEO, Healx is a generative AI enabled, clinical-stage, uncommon illness biotech firm advancing the following technology of drug discovery with a purpose to carry novel, efficient remedies to uncommon illness sufferers around the globe. By combining generative AI expertise with deep drug discovery and improvement experience, Healx can speed up the tempo, enhance the dimensions and enhance the prospect of success of uncommon illness remedy improvement with a purpose to ship world affected person influence.
The Healx drug discovery pipeline is powered by Healnet, an AI-driven discovery platform designed to determine clinically de-risked therapeutic alternatives for uncommon illnesses. Healnet incorporates current advances in generative AI to search out connections between organic and chemical entities that might be became new remedies.
Healx additionally introduced that it has obtained clearance from the U.S. Meals and Drug Administration (FDA) to proceed with its Section 2 scientific trial of HLX-1502. This trial will give attention to treating adults with NF1 and inoperable plexiform neurofibroma.
HLX-1502 is a pill taken orally that works in a different way than different remedies and gives a brand new and differentiated investigational remedy choice for sufferers with NF1
HLX-1502 has obtained Orphan Drug and Uncommon Pediatric Illness designations from the FDA for treating NF1. These FDA designations present a number of advantages to encourage the event of remedies for uncommon illnesses and additional spotlight HLX-1502’s potential to considerably enhance the lives of NF1 sufferers.
FinSMEs
02/08/2024
